You are here
Generic Version of Agrylin Cleared by FDA
Anagrelide Hydrochloride capsules are approved for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Anagrelide Hydrochloride capsules had annual sales of approximately $107 million, based on IMS data for the twelve months ended February 2005.
Source: Barr Pharmaceuticals, Inc.